An FDA advisory committee voted 18-1 in favor of approving romosozumab to treat postmenopausal women with osteoporosis.
Do Osteoporosis Screening Guidelines Meet Patient Needs?
A recent study found that clinical practice guidelines for osteoporosis screening vary in quality and recommendations—even within the same country. Assessing guidelines from 13 countries, researchers found osteoporosis screening standards have not improved over time and many fail to include patients in guideline development…
Anxiety Is an Independent Risk Factor for Bone Fractures
Higher anxiety levels in postmenopausal women may put them at increased risk of fracture and should be considered when assessing a woman’s risk of osteoporosis as well. This is the conclusion of a study recently published in the journal Menopause that looked at the role of anxiety in bone health.1 Specifically, the study examined the…
A Balancing Act: Tips to Ensure Optimal Screening & Treatment for Osteoporosis
Patients with rheumatic diseases may be undertreated for osteoporosis. To decrease fracture risk for at-risk patients, rheumatologists can engage patients in shared decision making with regular screening and education about treatment options…
Antibodies Against Oxidized Phospholipids Protect Against Osteoporosis
It has long been known that hyperlipidemia adversely affects bone, but the exact pathologic mechanism(s) underlying hyperlipidemia-induced bone loss has not been fully understood. Until now. Pathogenesis of Osteoporosis New research by Ambrogini and colleagues shows that oxidation-specific epitopes derived from lipid peroxidation contribute to the pathogenesis of osteoporosis.1 Importantly, the research shows that innate…
Taking Vitamin D Supplements May Not Improve Bone Health
(Reuters Health)—Vitamin D supplementation may not improve bone density or prevent fractures and falls in adults, a large new analysis suggests. After combining data from 81 randomized controlled trials, researchers found no bone benefits from supplementing the vitamin, according to the report in The Lancet Diabetes & Endocrinology, online October 4. “Our results show that…
Bone Mineral Density Most Important Determinant of Fracture Risk
NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were…
Osteoporosis Drugs Tied to Lower Fracture Risk & Health Costs
(Reuters Health)—Older women with osteoporosis who consistently take a bisphosphonate may have a lower risk of fractures and lower total health costs than their counterparts who stop taking these drugs, a U.S. study suggests. Researchers examined data on 294,369 women who were at least 66 years old, insured by Medicare and prescribed osteoporosis medicines for…
Improve Your Recognition & Treatment of Osteoporosis
BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…
Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis
NEW YORK (Reuters Health)—Levels of two bone markers currently recommended for evaluating postmenopausal women with osteoporosis have no association with hip fracture risk, according to a new study using Women’s Health Initiative data. “At least in these postmenopausal women, it was not a useful endeavor to check bone turnover markers to predict hip-fracture risk. That…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 19
- Next Page »